UC Davis Health Clinical Studies

A Study of the Experimental PET/CT Radiotracer "18F-avb6-Binding-Peptide" After COVID-19 (Coronavirus) Infection

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

Researchers at UC Davis have developed a new drug to aid in the detection of lung damage. This drug is called a “radiotracer." It attaches to damaged cells and shines a light that can be seen using a special camera, called a “positron emission tomography” or “PET” scanner. We hope this new radiotracer will improve the ability to locate possible lung damage. This new radiotracer is called Fluorine-18 Alpha-V Beta-6 Binding Peptide.

Other Study
Any, age 18 years and older

A Study to Test the Activity and Safety of Experimental Selinexor (KPT-330) for Severe COVID-19 (Coronavirus) Infection

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

Coronavirus disease 2019 (COVID-19) is caused by the single stranded RNA virus (SARS-CoV2). It may also cause an inflammatory response. This inflammation is harmful to your health. It can lead to: - multiorgan dysfunction (altered function of various organ systems such as heart, lung, and kidney), - respiratory failure and - even death. A protein called exportin 1 (XPO1) has been shown to be important in both the virus lifecycle and the inflammation caused by the virus. Inhibition of XPO1 by selinexor could lead to both anti-viral and anti-inflammatory activity. Selinexor is approved by the FDA for the use in certain patients with a type of cancer called multiple myeloma. It is considered experimental for use in COVID-19. Experimental means that it has not been approved by the FDA for the treatment of COVID-19.

Drug Study
Any, age 18 years and older

Serologic (blood-based) Response of COVID-19 (Coronavirus) Patients

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The novel coronavirus (COVID19) has caused a global pendemic. Some patients have had symptoms and were tested for the infection. Many others developed immunity from the virus, but never had symptoms. These patients can be identified by an antibody test (blood test). These are new tests and the accuracy of them has not been determined. We are asking for blood from patients who have been tested for COVID-19 to determine how well these new antibody blood tests work. We also would like to see how your immune system responded to the infection and arealso asking for saliva samples for testing of antibodies. Blood cells will be taken and in the lab exposed to the virus to see how they kill this new virus. We will also look at your blood cells under a microscope to see if there are any abnormalities.

Other Study
Any, age 18 years and older

Outcomes Related to COVID-19 (Coronavirus) Treated with Hydroxychloroquine Among In-Patients with Symptomatic Disease

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

We think hydroxychloroquine might help the body recover from COVID-19. We do not have enough information to know if it makes COVID-19 better or worse or has no effect. In laboratory studies, it appears that hydroxychloroquine can help kill the COVID-19 virus. Sometimes drugs that look like they might work in laboratory studies do not actually work when given to people. Some people who take hydroxychloroquine have side effects (things that the drug does that are not helpful and can be harmful). We do not know whether taking hydroxychloroquine: - is overall helpful, - is overall harmful, or - has no effect when it is taken for COVID-19. This study will test if hydroxychloroquine helps people recover from COVID-19.

Drug Study
Any, age 18 years or older

Testing the Safety and Effectiveness of Experimental Sarilumab in Hospitalized Patients With COVID-19 (Coronavirus)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

You are being asked to take part in a research study because you have the COVID‑19 virus. This study will test the safety and effectiveness of the experimental drug, sarilumab (study drug). This study is sponsored by Regeneron Pharmaceuticals, Inc. (“Regeneron”). Sarilumab (also known as Kevzara®) is considered an experimental drug in this study. It has not been approved by the FDA for the condition being studied. However, it has been approved in multiple countries for active rheumatoid arthritis. Sarilumab is a type of drug called a “monoclonal antibody”. An antibody is a special kind of protein that your immune (defense) system normally makes to fight bacteria and viruses. Scientists can now make antibodies in the laboratory for the treatment of many different diseases. Sarilumab has been specifically shown to block the action of a protein called interleukin-6 (IL-6) in your body. Interleukin-6 (IL-6) is a protein in the immune system that has been shown to play an important role in inflammation. Inflammation may be associated with symptoms and complications of COVID‑19. The main purpose of this study is to determine if sarilumab is safe and if it can decrease the amount of time you have COVID-19 symptoms.

Drug study, Phase 2/3
Any, age 18 years or older

Experimental Treatment with Remdesivir for Patients Hospitalized With Coronavirus Infection (COVID-19)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

There are no approved medications to treat COVID-19 because it is a new disease caused by a virus that was just identified in 2019 in China. Some people who become sick with COVID-19 have serious disease and must be hospitalized. This study will test a drug in adult patients that are hospitalized with COVID-19. The drug has been tested before in humans with other diseases. In this study, we would like to make sure that it is safe for use in humans with COVID-19 and see if it can improve patients’ health when they are sick with COVID-19. We are studying the experimental use of a drug called remdesivir. This drug has been studied in animals and in people. It is given as an infusion, which means that it is given through a plastic tube attached to a needle that is put into a vein in the arm. To find out if remdesivir (the study drug) works, we need to compare it to getting something that does not have the drug in it, something called a placebo. The placebo looks like the study drug but does not have the drug in it. Using a placebo is common in research studies. The placebo is also given as an infusion. Some people in the study will get the placebo.

Other study, Phase 2
Any, age 18 to 99 years old